{"id":"NCT01630135","sponsor":"GlaxoSmithKline","briefTitle":"Study FFR116364, a Placebo-controlled Study of GW685698X in Paediatric Subjects With Perennial Allergic Rhinitis","officialTitle":"Study FFR116364, a Double-blind, Placebo-controlled Study of GW685698X in Paediatric Subjects With Perennial Allergic Rhinitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-06","primaryCompletion":"2012-08","completion":"2012-08","firstPosted":"2012-06-28","resultsPosted":"2013-05-01","lastUpdate":"2017-01-11"},"enrollment":261,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Rhinitis, Allergic, Perennial"],"interventions":[{"type":"DRUG","name":"Fluticasone furoate","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"GW685698X","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Efficacy and safety of GW685698X (55 µg/day, q.d.) nasal spray over a period of 2 weeks in Japanese paediatric subjects ages 6 to \\< 15 years with perennial allergic rhinitis will be evaluated compared with placebo.","primaryOutcome":{"measure":"Mean Change From Baseline in the 3 Total Nasal Symptom Score (3TNSS) Over the Entire Treatment Period","timeFrame":"Baseline through the entire treatment period (2 weeks)","effectByArm":[{"arm":"Fluticasone Furoate 55 µg Per Day","deltaMin":-1.98,"sd":0.12},{"arm":"Placebo","deltaMin":-0.89,"sd":0.12}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":11},"locations":{"siteCount":22,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":131},"commonTop":["Nasopharyngitis","Epistaxis","Bronchitis","Nasal discomfort","Alanine aminotransferase increased"]}}